tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
PTC Therapeutics: Sephience Outperformance and Votoplam De‑Risking Drive Upgraded Medium-Term Growth Outlook and Buy Rating
PremiumRatingsPTC Therapeutics: Sephience Outperformance and Votoplam De‑Risking Drive Upgraded Medium-Term Growth Outlook and Buy Rating
1M ago
PTC Therapeutics Posts Strong 2025 Results, Updates 2026 Outlook
Premium
Company Announcements
PTC Therapeutics Posts Strong 2025 Results, Updates 2026 Outlook
1M ago
PTC Therapeutics sees FY25 product, royalty revenue $823.4M
Premium
The Fly
PTC Therapeutics sees FY25 product, royalty revenue $823.4M
1M ago
PTC Therapeutics: Strong Growth Potential Driven by R&D Expertise and Successful Sephience Launch
PremiumRatingsPTC Therapeutics: Strong Growth Potential Driven by R&D Expertise and Successful Sephience Launch
2M ago
Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls
Premium
The Fly
Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls
3M ago
Cadrenal Therapeutics appoints Lee Golden to board of directors
Premium
The Fly
Cadrenal Therapeutics appoints Lee Golden to board of directors
3M ago
Strong Market Penetration and Strategic Pricing Propel PTC Therapeutics to a Buy Rating
PremiumRatingsStrong Market Penetration and Strategic Pricing Propel PTC Therapeutics to a Buy Rating
3M ago
PTC Therapeutics price target raised to $50 from $44 at Goldman Sachs
Premium
The Fly
PTC Therapeutics price target raised to $50 from $44 at Goldman Sachs
3M ago
PTC Therapeutics’ Earnings Call Highlights Success and Challenges
Premium
Company Announcements
PTC Therapeutics’ Earnings Call Highlights Success and Challenges
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100